COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech
30/05/2025
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech Avec l’acquisition de cette plateforme d'ophtalmologie de premier plan auprès de MidEuropa, le Groupe vise à [...]
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
30/05/2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit [...]
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
30/05/2025
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib in relapsing and primary [...]
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30/05/2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of [...]
Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
30/05/2025
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des [...]
Leading with Light: MUSE Microscopy Illuminates the Next Era of Oncology at ASCO
29/05/2025
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy , (the “Company”, “we”, “our”) a leader in slide-free, tissue-to-digital™ pathology solutions, is excited to announce its participation in the upcoming [...]
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
29/05/2025
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today [...]
Kane Biotech Announces First Quarter 2025 Financial Results
29/05/2025
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results. First Quarter 2025 Financial [...]
Tarsus to Participate in Upcoming Investor Conferences
29/05/2025
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45 th [...]
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
29/05/2025
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek [...]
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
29/05/2025
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan [...]
Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer
29/05/2025
CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief [...]
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
29/05/2025
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL [...]
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
29/05/2025
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio [...]
Alumis to Present at the Jefferies Global Healthcare Investor Conference
29/05/2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today [...]
CooperCompanies Announces Second Quarter 2025 Results
29/05/2025
SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue [...]
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
29/05/2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
29/05/2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and [...]
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
29/05/2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery [...]

Pages